ALLN 177

Drug Profile

ALLN 177

Alternative Names: ALLN-177

Latest Information Update: 01 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Allena Pharmaceuticals
  • Class Enzymes
  • Mechanism of Action Oxalate inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary hyperoxaluria; Hyperoxaluria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hyperoxaluria
  • Preclinical Primary hyperoxaluria

Most Recent Events

  • 27 Jul 2017 ALLN 177 receives Orphan Drug status for Primary hyperoxaluria in European Union
  • 13 Jul 2017 Preclinical trials in Primary hyperoxaluria in USA (PO)
  • 13 Jul 2017 ALLN 177 receives Orphan Drug status for Primary hyperoxaluria in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top